Does Caffeine Facilitate Human Reward Learning Behaviors? (ADoRe)

Y

Yu-Shiuan Lin

Status

Enrolling

Conditions

Caffeine

Treatments

Dietary Supplement: caffeine
Dietary Supplement: mannitol

Study type

Interventional

Funder types

Other

Identifiers

NCT05325502
CChronobiology

Details and patient eligibility

About

"Learning from the rewards" is underlying the formulation of knowledge and habits in daily life. Caffeine is the most commonly used "psychoactive" substance that could change one's mind state by affecting the brain and nervous system. By such effects, caffeine enhances reward signals - dopamine - in human brains. In this research study, we will find out whether taking caffeine acutely or daily can enhance reward learning processes.

Full description

Reward learning is associated with the formulation of habits, memories, and beliefs. Positive (receiving an unexpected reward) and negative reinforcement (eliminating an unwanted state) learning are primarily modulated by striatal dopamine D1 and D2 receptors. While caffeine, a psychostimulant regularly consumed by 80% worldwide population, is known to facilitate striatal dopamine signaling, the potential of caffeine on enhancing reward learning in humans remains unknown. In this double-blind, randomized, crossover study, 36 young healthy non-smoking habitual caffeine consumers (daily dose 100 - 450 mg) who are aged between 18 and 40 will be examined. Each of the 36 participants (18 F, 18 M) will undergo an acute caffeine condition, a daily caffeine condition, and a daily placebo condition. Each condition consists of 7 days - 6 ambulatory days followed by 1 laboratory visit. In the ambulatory part, participants will abstain from caffeine, nicotine, medications, and recreational drugs. Compliance to the interventions and abstinence of caffeine will be monitored by salivary caffeine concentration every day. Bedtime and sleep quality will be recorded in sleep diary. On the laboratory visit, participants will perform cognitive tasks on a 2.5h task battery, which includes a probabilistic selection task, a motor inhibition task, and a salience attribution test. We also measure their arousal and anxiety levels 1h after the second intake on the laboratory visit. We will use Bayes factor analyses to test our confirmatory hypotheses (on the primary outcomes): 1) Caffeine enhances the accuracy of reward learning; 2) Daily intake of caffeine facilitates the negative reinforcement compared to acute its intake. On the secondary outcomes, we examine the exploratory hypotheses that caffeine enhances motor inhibition and motivational salience. Arousal and anxiety levels will be examined as a covariate which potentially contribute to the caffeine-induced changes in reward learning performance.

Enrollment

36 estimated patients

Sex

All

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age ≥ 18 and ≤ 40
  • Clinically healthy
  • Non-smokers

Exclusion criteria

  • Habitual caffeine intake < 100 mg or > 450 mg
  • Pregnant or lactating women
  • Women using hormonal contraceptives
  • BMI < 18.5 or > 29.9
  • Sleep disturbance or extreme chronotypes
  • Nicotine or recreational drug users
  • Depression, anxiety, psychosis, or neurologic disorders
  • Severe heart or cardiovascular diseases
  • Diabetes or metabolic diseases
  • Under chronic medications
  • Incapable to operate the tasks or comprehend the study information in German or English
  • Users of the Bopomo alphates utilized as stimuli in the reward learning tasks
  • Current enrolment in other clinical trials

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Triple Blind

36 participants in 3 patient groups, including a placebo group

Placebo
Placebo Comparator group
Description:
7 days placebo intake.
Treatment:
Dietary Supplement: mannitol
Acute caffeine
Active Comparator group
Description:
6 days placebo followed by 1 day caffeine intake.
Treatment:
Dietary Supplement: mannitol
Dietary Supplement: caffeine
Daily caffeine
Experimental group
Description:
7 days caffeine intake
Treatment:
Dietary Supplement: caffeine

Trial contacts and locations

1

Loading...

Central trial contact

Yu-Shiuan Lin, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems